Salvage Chemotherapy with R-DHAP in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma.

Autor: Schirmbeck NG; a Center for Integrated Oncology (CIO) , University Hospital Bonn , Bonn , Germany., Mey UJ; b Departement Innere Medizin , Medizinische Onkologie und Hämatologie , Kantonsspital Graubünden, Chur , Switzerland., Olivieri A; c Department of Hematology , Ancona University , Ancona , Italy., Ko YD; d Internistische Onkologie , Johanniter Krankenhaus , Bonn , Germany., Kaiser U; e Onkologisches Zentrum , St. Bernward Krankenhaus , Hildesheim , Germany., Flieger D; f Medizinische Klinik I , GPR Klinikum Rüsselsheim , Rüsselsheim , Germany., Witzens-Harig M; g Zentrumfür Innere Medizin (KrehlKlinik) , Innere Medizin V: Klinik für Hämatologie, Onkologie, Rheumatologie, Universitäts Klinikum Heidelberg , Heidelberg , Germany., Schmidt-Wolf IG; a Center for Integrated Oncology (CIO) , University Hospital Bonn , Bonn , Germany.
Jazyk: angličtina
Zdroj: Cancer investigation [Cancer Invest] 2016 Sep 13; Vol. 34 (8), pp. 361-72. Date of Electronic Publication: 2016 Sep 16.
DOI: 10.1080/07357907.2016.1212062
Abstrakt: This analysis reports on 72 patients with relapsed or refractory non-Hodgkin lymphoma who were treated with R-DHAP salvage chemotherapy regimen followed by high-dose chemotherapy and stem cell transplantation. The overall remission rate was 58.3%. Median time of follow-up was 28.7 months. Median progression-free survival was 29 months, estimated median overall survival was 37 months. Within a matched pair analysis these results were compared to a group that received DHAP salvage therapy without rituximab showing similar overall response rates and better estimated five-year overall survival of 59.2% versus 43.5%. R-DHAP therapy was shown to be effective and feasible with acceptable toxicity.
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje